Table 2.
Univariable analysis and multivariable analysis for overall survival in our cohort
| Characteristic | Univariable analyses |
Multivariable analyses |
||
|---|---|---|---|---|
| Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
| Age (yr) | ||||
| ≤ 47 | Reference | Reference | ||
| > 47 | 1.07 (0.73-1.56) | 0.728 | 0.86 (0.58-1.29) | 0.467 |
| Sex | ||||
| Male | Reference | Reference | ||
| Female | 1.05 (0.63-1.745) | 0.846 | 1.30 (0.77-2.19) | 0.336 |
| No. of metastatic lesions | ||||
| ≤ 3 | Reference | Reference | ||
| > 3 | 2.53 (1.72-3.72) | < 0.001 | 1.92 (1.26-2.94) | 0.003 |
| T categorya) | ||||
| T1-2 | Reference | Reference | ||
| T3-4 | 1.01 (0.62-1.65) | 0.964 | 1.05 (0.63-1.73) | 0.857 |
| N categorya) | ||||
| N0-1 | Reference | Reference | ||
| N2-3 | 1.97 (1.19-3.28) | 0.009 | 1.69 (0.99-2.90) | 0.054 |
| PCT regimen | ||||
| TPF | Reference | Reference | ||
| TP | 1.05 (0.61-1.81) | 0.850 | 1.07 (0.61-1.88) | 0.819 |
| PF | 1.23 (0.73-2.06) | 0.433 | 1.39 (0.80-2.41) | 0.242 |
| Other regimens | 1.41 (0.82-2.43) | 0.218 | 1.61 (0.91-2.84) | 0.104 |
| Pre-treatment EBV DNA (copy/mL) | ||||
| < 25,000 | Reference | Reference | ||
| ≥ 25,000 | 1.75 (1.19-2.58) | 0.005 | 1.14 (0.73-1.79) | 0.567 |
| EBV DNA after PCT | ||||
| Undetectablb) | Reference | Reference | ||
| Detectableb) | 2.79 (1.90-4.11) | < 0.001 | 1.91 (1.23-2.96) | 0.004 |
| LRRT | ||||
| No | Reference | Reference | ||
| Yes | 0.39 (0.27-0.59) | < 0.001 | 0.48 (0.31-0.75) | 0.001 |
| MRT | ||||
| No | Reference | Reference | ||
| Yes | 0.77 (0.50-1.19) | 0.243 | 1.21 (0.76-1.91) | 0.422 |
CI, confidence interval; PCT, palliative chemotherapy; TPF, cisplatin plus docetaxel plus 5-fluorouracil; TP, cisplatin plus docetaxel; PF, cisplatin plus 5-fluorouracil; EBV, Epstein-Barr virus; LRRT, locoregional radiotherapy; MRT, metastasis radiotherapy.
a)
According to the 7th edition of the Union for International Cancer Control/American Joint Committee on Cancer staging system,
b)
Undetectable/detectable EBV DNA levels after neoadjuvant chemotherapy were based on a cutoff value of 0 copy/mL, a Cox proportional hazard model was used to perform multivariate analyses.